At a glance
| Attribute | AOD-9604 | Tesamorelin |
|---|---|---|
| Class | hGH 176-191 fragment | GHRH analogue |
| Mechanism | Lipolysis / fat-oxidation pathways | Endogenous GH + IGF-1 release |
| Affects IGF-1? | No | Yes |
| Research strength | Mostly preclinical | Extensive clinical literature |
| Half-life | Short (minutes) | ~26 minutes (sustained GH pulse) |
Mechanism
AOD-9604 is a synthetic fragment corresponding to the C-terminal 176–191 of human GH; research suggests it modulates lipolysis without binding the GH receptor itself. Tesamorelin is a stabilised GHRH analogue that triggers endogenous GH release from the pituitary.
Body-composition research
Tesamorelin is best characterised in clinical research on visceral adipose tissue reduction in HIV-associated lipodystrophy. AOD-9604's body-composition data is largely preclinical and animal-based.
Side-effect signal
Because AOD-9604 does not raise IGF-1, its side-effect profile in research is distinct from GH-axis compounds. Tesamorelin can show GH-related effects (joint stiffness, glucose shifts) consistent with its mechanism.
Which fits which study
Investigators studying lipolysis pathways without confounding GH/IGF-1 movement favour AOD-9604. Investigators studying endogenous GH axis manipulation favour Tesamorelin.
Frequently asked questions
Are AOD-9604 and Tesamorelin both GH-related?+
Yes, but in opposite directions. AOD-9604 is a fragment of human growth hormone that acts on lipolysis pathways without raising IGF-1. Tesamorelin is a GHRH analogue that drives endogenous GH and IGF-1 release.
Which is better-studied for visceral fat?+
Tesamorelin has the more extensive clinical research base for visceral adipose reduction. AOD-9604's data is largely preclinical.
Do they affect IGF-1 differently?+
Tesamorelin elevates IGF-1 via GH release; AOD-9604 does not.